Frank Wu
Impact in
- Oncology top 5%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Molecular Biology top 5%
- Melanoma and MAPK Pathways
- Histone Deacetylase Inhibitors Research
- PI3K/AKT/mTOR signaling in cancer
Papers in
-
- Melanoma and MAPK Pathways 4
- Oncology 13
- Pancreatic and Hepatic Oncology Research 4
- Peptidase Inhibition and Analysis 3
- Co-authors
- Reinhard Dummer (4 shared papers)Mohammed Milhem (4 shared papers)James Larkin (4 shared papers)Paul Nathan (4 shared papers)Peter Hersey (4 shared papers)Lev Demidov (4 shared papers)Dirk Schadendorf (4 shared papers)Piotr Rutkowski (4 shared papers)
- Journals
- Journal of Clinical Oncology (9 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)Cancer Research (3 papers)Journal of Medicinal Chemistry (2 papers)Blood (2 papers)
- Partner nations
- United StatesChinaFrance
In The Last Decade
Frank Wu
37 papers receiving 2.0k citations
Frank Wu's Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 789
- Molecular Biology 1.2k
- Reproductive Medicine 128
- Cancer Research 139
- Pathology and Forensic Medicine 132
Countries citing papers authored by Frank Wu
This map shows the geographic impact of Frank Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Wu more than expected).
Fields of papers citing papers by Frank Wu
This network shows the impact of papers produced by Frank Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Wu. The network helps show where Frank Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Frank Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1071 |
| 2 | 2015 | 252 | |
| 3 | 2006 | 118 | |
| 4 | 2011 | 96 | |
| 5 | 2005 | 63 | |
| 6 | Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. | 2002 | 50 |
| 7 | 2020 | 49 | |
| 8 | 2019 | 42 | |
| 9 | 2014 | 32 | |
| 10 | 2020 | 23 | |
| 11 | 2010 | 20 | |
| 12 | 2022 | 19 | |
| 13 | 2012 | 18 | |
| 14 | 2013 | 18 | |
| 15 | 2010 | 16 | |
| 16 | 2011 | 14 | |
| 17 | 2016 | 14 | |
| 18 | 2024 | 10 | |
| 19 | 2012 | 9 | |
| 20 | 2023 | 8 |
About Frank Wu
Frank Wu is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Surgery and Cell Biology, having authored 41 papers that have together received 2.0k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Cancer Mechanisms and Therapy (4 papers), Melanoma and MAPK Pathways (4 papers), Advanced Breast Cancer Therapies (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Peptidase Inhibition and Analysis (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (789 citations), Molecular Biology (1.2k citations), Reproductive Medicine (128 citations), Cancer Research (139 citations) and Pathology and Forensic Medicine (132 citations). Frank Wu has collaborated with scholars based in United States, China and France. Frequent co-authors include Reinhard Dummer, Mohammed Milhem, James Larkin, Paul Nathan, Peter Hersey, Lev Demidov, Dirk Schadendorf, Piotr Rutkowski, Laurie Sherman and Claus Garbe. Their work appears in journals such as Journal of Clinical Oncology, Bioorganic & Medicinal Chemistry Letters, Cancer Research, Journal of Medicinal Chemistry and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.